Here's the short version. Semaglutide, the drug in Ozempic and Wegovy, does reach the brain's appetite centers, and that's a big part of how it works. FDA’s review did not find an increased risk of the psychiatric outcomes it assessed. The hope that it protects memory took a hit in 2025, when two large trials came up empty.
What Ozempic is approved for: no brain or mood use
Ozempic is approved to manage blood sugar in adults with type 2 diabetes and to lower heart and kidney risks in some of them. It isn't approved for any brain or mood condition.
All three of its labeled uses are for adults with type 2 diabetes. They are blood-sugar control with diet and exercise, lower risk of major heart events with heart disease, and lower risk of kidney decline with chronic kidney disease [1]. Wegovy, the same drug at weight-management doses, is approved for weight, heart-risk reduction and a liver condition called MASH [2].
How semaglutide affects appetite in the brain
GLP-1 drugs act on receptors in brain areas that regulate hunger and fullness. That's the main way they cut how much people eat.
GLP-1 is a physiological regulator of appetite and caloric intake, and the GLP-1 receptor is present in several areas of the brain involved in appetite regulation.[2]
The label adds that in animal studies, semaglutide reached and activated nerve cells in brain regions that control food intake [2]. In people, a 20-week trial measured the effect directly. On semaglutide, hunger dropped and fullness rose. People reported better control of eating and fewer, weaker food cravings. At a buffet lunch they ate 35% less than people on placebo [4]. Novo Nordisk, the maker, ran that trial. Eating that much less can leave some people tired, which does Wegovy give you energy? covers.
That's what people often mean by "Ozempic brain": the quieter pull of food. It's a media phrase, not a medical term.
"Is Ozempic reshaping the brain?" Not in the way headlines suggest
That phrase comes from news coverage of appetite and reward research. The trials here measured appetite, mood risk and memory, not lasting changes to brain structure.
Acting on brain receptors is how the drug curbs appetite, the same way many medicines act on the brain. It doesn't mean the brain is being rebuilt. If a headline claims more, look for a human trial behind it.
Mood, anxiety and depression: FDA found no added risk
In January 2026, FDA concluded that GLP-1 drugs don't raise the risk of suicidal thoughts or behavior. Its pooled analysis showed no increased risk of anxiety, depression, irritability or psychosis either.
FDA pooled 91 placebo-controlled trials with 107,910 patients. It also compared more than 2.2 million people with type 2 diabetes starting a GLP-1 drug or a different diabetes drug, and found no increased risk of self-harm. FDA then asked the makers of Saxenda, Wegovy and Zepbound to remove the suicidal-thoughts warning from their labels. Diabetes-only labels like Ozempic's never carried it [3]. Wegovy's label now lists that section as removed in February 2026 [2].
| Question | What the evidence says | Source |
|---|---|---|
| Does it act on appetite in the brain? | Yes, the main way it cuts food intake | Wegovy label [2]; Friedrichsen 2021 [4] |
| Does it raise suicide risk? | No increased risk found | FDA, January 13, 2026 [3] |
| Anxiety, depression, psychosis? | No increased risk across 91 trials | FDA, January 13, 2026 [3] |
| Does it treat anxiety or depression? | Not shown | No treatment trial result |
| Does it slow Alzheimer's? | No, in evoke and evoke+ | Cummings 2026 [5] |
| Approved for any brain condition? | No | Ozempic label [1] |
Can Ozempic help anxiety or depression? Not shown
No trial has shown it treats either. "No increased risk" isn't the same as a benefit.
FDA's review asked whether these drugs cause harm to mood. It didn't test whether they help. Some people feel better as they lose weight or get blood sugar under control, and that matters. But anxiety and depression have treatments with real evidence behind them. If either is your concern, raise it with your clinician on its own terms, not as a reason to start semaglutide.
Memory and Alzheimer's: two large trials found no slowing
Two large trials of oral semaglutide in early Alzheimer's, evoke and evoke+, did not slow cognitive or functional decline compared with placebo.
Together they randomized 3,808 adults aged 55 to 85 with amyloid-confirmed early Alzheimer's, at 566 sites in 40 countries. The trial used oral semaglutide up to 14 mg a day. At week 104, scores on a standard dementia scale had worsened about the same on semaglutide as on placebo, a difference of −0.08 points in evoke and 0.10 in evoke+. Neither was statistically significant. The authors concluded semaglutide "was not efficacious in slowing clinical progression." Novo Nordisk funded both trials, and both were stopped [5].
Parkinson's is a separate story with a different drug. In a 2024 trial of 156 people with early Parkinson's, lixisenatide, an older GLP-1 drug, slowed the worsening of movement scores over 12 months: −0.04 points vs +3.04 on placebo. Nausea hit 46% of people on it [6]. That's not semaglutide, and it was a mid-stage trial.
Wegovy and anxiety: the same answer
Wegovy is the same drug at a weight-management dose. FDA's 2026 review covered it by name, found no increased risk of anxiety or depression, and its label no longer carries a suicidal-thoughts warning.
As with Ozempic, "doesn't raise risk" isn't "treats." Wegovy isn't approved or proven for anxiety [3] [2]. On tirzepatide instead? See does Zepbound help with anxiety?
Can semaglutide support brain health? Not shown so far
It's being studied, but the largest trials so far, evoke and evoke+ in early Alzheimer's, found no slowing of decline [5].
Earlier hope came from animal work and from observational studies in people with diabetes or obesity, which the evoke authors cite as their reason for testing it. Those designs can't show cause. The randomized test didn't confirm the hope.
What to tell your prescriber
Report any new or worsening low mood, anxiety or unusual changes in behavior, as FDA advises [3].
Keep taking the medicine as prescribed while you talk it through. If your real goal is metabolic health, our metabolic shortlist lays out the options. If sleep or recovery is what's off, see the sleep and recovery shortlist. A related question: does semaglutide help with inflammation? Not sure where to start? Take the 30-second match.